Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain

Balasubramanian Chandramouli1,†, Gerry Melino2,3 and Giovanni Chillemi4,5

1 Scuola Normale Superiore, Pisa, Italy
2 Department of Experimental Medicine, TOR, University of Rome ‘Tor Vergata’, Italy
3 Medical Research Council, Toxicology Unit, Department of Pathology, Cambridge University, Cambridge, UK
4 Department for Innovation in Biological, Agro-Food and Forest Systems (DIBAF), University of Tuscia, Viterbo, Italy
5 National Council of Research, CNR, Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Bari, Italy

Keywords
AdoMet; C-terminal domain; lysine methylation; molecular dynamics; p53; Smyd2

Correspondence
B. Chandramouli, Scuola Normale Superiore, Piazza dei Cavalieri 7, I-56126, Pisa, Italy
Tel: +39-050-508406
E-mail: bala.chandramouli@sns.it
and
G. Chillemi, DIBAF, University of Tuscia, 01100 Viterbo, Italy
Tel: +39-06-44486706
E-mail: gchillemi@unitus.it

†Present address
Compunet, Istituto Italiano di Tecnologia (IIT), Genova, Italy

(Received 26 February 2019, revised 1 May 2019, accepted 8 May 2019, available online 21 May 2019)
doi:10.1002/1878-0261.12502

1. Introduction
Smyd2 is a member of five lysine methyltransferases constituted by a suppressor of variegation, enhancer of zeste, trithorax (SET) domain (InterPro ID IPR001214), intercalated by a myeloid-nervy-DEAF1 (MYND) zinc binding domain (InterPro ID IPR002893). Smyds catalyze the monomethylation of histone and nonhistone lysine residues, using the S-adenosylmethionine methyl donor cofactor (AdoMet/SAM) and releasing the product S-adenosylhomocysteine (AdoHcy/SAH) (Spellmon et al., 2015).

Smyd2 targets H3 (Lys4, Lys36), but its peculiarity among the Smyds lies in the vast broad spectrum of nonhistone targets that comprehend around twenty proteins, such as p53 (Lys370), retinoblastoma (Lys860), estrogen receptor ERα (Lys266), PARP1 (Lys528), HSP90 (Lys531, Lys574), and, recently, BMPR2 (Brown et al., 2006; Foreman et al., 2011; Gao et al., 2017; Gottlieb et al., 2002; Hamamoto

Abbreviations
MD, molecular dynamics; MYND, myeloid-nervy-DEAF1; PCA, principal component analysis; PDB, protein data bank; RMSF, root-mean-square fluctuation; SET, suppressor of variegation, enhancer of zeste, trithorax.
et al., 2004; Van Aller et al., 2012). Recent proteomics studies have identified several additional potential Smyd2 substrates (Ahmed et al., 2016; Olsen et al., 2016).

Another methyltransferase, Set9, also targets p53 (at Lys372) (Chuikov et al., 2004). This may be of particular interest in DNA damage response (Nemajerova et al., 2018; Parrales et al., 2018), cell cycle arrest (Engeland, 2018; Wu and Prives, 2018), tumor suppression (Charni et al., 2018; Kaiser and Attardi, 2018) and in particular in cancer progression (Aubrey et al., 2018; Baugh et al., 2018; Kim and Lozano, 2018), when considering the pivotal role of p53 in these cellular mechanisms (Furth and Aylon, 2017; Furth et al., 2018; Sullivan et al., 2018). Consequently, the interaction between p53 and Smyd2 could be of high relevance. Methylation of Lys370 by Smyd2 reduces its binding efficiency to promoter genes, thereby repressing p53 transcriptional activity (Huang et al., 2006). The opposite functional effect is observed when Set9 methylates Lys372, with an increase of stability and activity of p53 (Marouco et al., 2013). A fine tuning of p53 transcriptional activity, therefore, is obtained via alternative methylation by Smyd2 on Lys370 and Set9 on Lys372.

Different in vivo studies have demonstrated the role played by Smyd2 in cancer initiation and progression (Bagislar et al., 2016; Reynoird et al., 2016). In line, downregulation of Smyd2 by small interfering RNA in cells promotes p53-mediated apoptosis, while its overexpression in esophageal squamous cell carcinoma is inversely correlated with patients survival rate (Komatsu et al., 2009). Smyd2 is also highly expressed in pediatric acute lymphoblastic leukemia, and higher expression level is correlated with bad prognosis (Sakamoto et al., 2014). The important role played by Smyd2 in cancer biology has spurred the development of cell-active inhibitors (Ferguson et al., 2011; Nguyen et al., 2015; Sweis et al., 2015). Recent evidences, however, show no impact of Smyd2–3 inhibition on cancer cell proliferation in vitro (Thomenius et al., 2018). Smyd2 and 3, therefore, could play a role in other steps of oncogenesis such as an early initiation step of oncogenesis, or in cell growth relevant only in vivo, like the regulation of the tumor microenvironment, angiogenesis, or immune evasion (Mazur et al., 2014; Thomenius et al., 2018). Further studies on the functional mechanism of Smyds are clearly needed.

From a structural point of view, the N- and C-terminal domains of Smyd2 form a clamp in which the substrate is inserted in a position in which it can receive the methyl group from AdoMet (Fig. 1A,B). Recently, we carried out a molecular dynamical study of Smyd2, highlighting its differential substrate crevice characteristics as compared to Smyd3 (Chandramouli and Chillemi, 2016; Chandramouli et al., 2016). From these studies, a critical role of the Smyds C-terminal domain emerges that orchestrates the catalytic cycle.

Previously, we have also performed dynamic studies on p53 in monomeric (Chillemi et al., 2013) and tetrameric (Chillemi et al., 2017; D’Abramo et al., 2016) conformation, showing a relevant induced-fit interaction of the p53 C-terminal domain with the DNA-binding domain. Here, we have performed μ-second molecular dynamics (MD) simulations to further understand the underlying molecular events regulating the Smyd2 catalytic cycle.

2. Materials and methods

2.1. Model generation and simulation protocol

Atomic coordinates for binary Smyd2-AdoMet (PDB ID: 3TG4) and ternary Smyd2-AdoHcy-p53 (PDB ID: 3TG5) complexes were extracted from better resolved X-ray crystallographic structures from PDB (Wang et al., 2011). Histidine protonation states were assigned based on the consensus predictions by H++ (v3.1), Protoss and Propka programs (Anandakrishnan et al., 2012; Bietz et al., 2014; Li et al., 2005). All simulations were performed with Amber package (v14) treating the protein with ff14SB forcefield (Hornak et al., 2006). Parameters for AdoMet and AdoHcy were adapted from Amber ff10 forcefield and a previous study (Hornak et al., 2006; Markham et al., 2002; Wang et al., 2000). The partial charges were obtained after a geometry optimization at HF/6-31G* level of theory using Gaussian (Gaussian 09; Gaussian Inc., Wallingford, CT, USA), followed by fitting the electrostatic potential with the restrained electrostatic potential procedure using RED tools (Bayly et al., 1993; Vanquelef et al., 2011). Dihedral restraints were applied during optimization to retain enzyme-bound conformations of AdoMet and AdoHcy. Zinc ions and the associated protein residues coordinated to the ion were treated with ZAFF parameters (Li et al., 2013; Peters et al., 2010). The starting structures were placed in a cubic box of TIP3P water model that extended up to ~15 Å from solute surface (Jorgensen et al., 1983). Additional counterions were added to achieve charge neutrality. All systems were subjected to elaborate equilibration as detailed in our previous reports (Chandramouli and Chillemi, 2016; Chandramouli et al., 2016). Production simulations were performed in NVT ensemble for 1 μs for each system, and
snapshots in the trajectory were saved at intervals of 10 ps. The simulation conditions included periodic boundary conditions, constraining covalent heavy atom–hydrogen bonds via SHAKE (Ryckaert et al., 1977), 2 fs time step for numerical integration, PME method for calculating long-range electrostatic interactions (Darden et al., 1993), 12 Å cutoff for short-range nonbonded interactions, temperature regulation with Langevin coupling using a collision frequency of 2.0 ps\(^{-1}\) (Izaguirre et al., 2001).

2.2. MD Trajectories analysis

For all root-mean-square (RMS) fitting, the respective X-ray structures were used as the reference. Unless stated otherwise, reference to backbone means C\(_a\), C, N atoms. Dynamic cross-correlation matrix was computed considering the backbone coordinates as follows,

\[
C_{ij} = \frac{\langle \Delta r_i \Delta r_j \rangle}{\sqrt{\langle \Delta r_i^2 \rangle} \sqrt{\langle \Delta r_j^2 \rangle}}
\]

where \(\Delta r_i\) is the displacement of \(i\)th atom from the mean position and \(<>\) represents the ensemble average over the analyzed portion of trajectory. Interaction energies and atom distances were calculated on the last 900 ns portion of the trajectories considering a snapshot every 100 ps (for a total of 9000 analyzed conformations). Principal component analysis (PCA) was performed by diagonalizing the covariance matrix obtained from atomic fluctuations after removing
rotations and translations by fitting the snapshots onto the X-ray structure (Amadei et al., 1993). To this purpose, a concatenated artificial trajectory was generated with snapshots from respective simulations obtained at 100 ps intervals over the last 900 ns. This permitted to project the frames yielded from the independent simulations on a common plane. Geometric angles (Chandramouli and Chillemi, 2016 for definitions) were calculated after fitting the trajectories over the N-terminal domain of the X-ray structures. All above analyses were performed using AMBERTOOLS (v1.5), GROMACS utilities (v.5.0.7) or codes in-house written using MDAnalysis (Michaud-Agrawal et al., 2011; Roe and Cheatham, 2013; Van Der Spoel et al., 2005). Graphical plots and figures were generated with Matplotlib (Hunter, 2007; Pettersen et al., 2004). Clustering was performed using hierarchical density-based method as implemented in hdbscan library (Campello et al., 2013; Campello et al., 2015; McInnes et al., 2017).

3. Results and Discussion

In order to improve our understanding of the Smyd2 catalytic cycle, here we carried out μ-second MD simulations of the following systems (see Fig. 1): Smyd2 in complex with AdoMet cofactor (Model-A); Smyd2-AdoMet-p53 peptide (unmethylated) complex (Model-B); Smyd2-AdoHcy-p53 peptide (methylated at Lys370) complex (Model-C); and Smyd2-AdoMet in complex with the p53 peptide methylated at Lys372 (Model-D).

In the following, we report structural elements that describe the conformational rearrangements and flexibility of Smyd2 and p53 peptides; the global motion of Smyd2 protein associated in its binary and ternary states, and finally, we highlight the dynamical characteristics of unmethylated and methylated p53 peptides as they bound to Smyd2 (see Fig. S1). The following color code is adopted in the figures: Model-A (black), Model-B (gray), Model-C (red), and Model-D (blue), as reported also in Fig. 1C.

3.1. Peptide substrates restrict the motion of Smyd2 C-terminal domain

The structural rearrangements during the simulation with respect to the starting X-ray configuration were monitored via estimating the backbone RMSD for Smyd2 and p53 peptides (Fig. S2). The time evolution of RMSD values shows a higher deviation in the binary system (Model-A) compared to the ternary systems (Fig. S2A), and the RMSD values are uniformly distributed around a higher mean of 3.2 (± 0.4). This indicates a larger structural relaxation in the absence of the substrate peptide. Among the ternary systems, RMSD values of Model D (p53 peptide with methylated Lys372) show a remarkable stability, while the two models B and C (unmethylated lysines and methylated at Lys370, respectively) fluctuate during the simulations up to 3 Å. The mean RMSD for models B–D are 2.0 (± 0.3), 1.9 (± 0.5), and 1.4 (± 0.2) Å, respectively. First, there results already show the great influence played by the bound p53 peptide on the overall dynamics of Smyd2, including the capability to discriminate between the two methylated lysines.

Further, the distribution of RMSD values calculated separately for Smyd2’s N- and C-terminal domains (hereinafter, NTD and CTD) shows a high overlap for the NTD across the all simulated models (Fig. S2B). For the CTD, interestingly, the RMSD distribution in the binary case is shifted toward higher values with respect to the ternary ones. Overall, these results imply that the larger RMS deviations observed in the binary simulation are driven by the structural relaxation of the CTD, while this remains relatively restricted in the ternary ones (i.e., in the presence of the substrate peptides). Time-evolved RMSD variations for the p53 peptides show a stable profile for the methylated at Lys372 system (Model-D; Fig. S2C). In contrast, more fluctuations are observed for the unmethylated peptide (Model-B) and the p53 methylated at Lys370 (Model-C). All the following analyses were restricted to the last 900 ns of the trajectories.

To identify the flexible segments of Smyd2 protein and p53 peptides, we calculated the per-residue averaged backbone root-mean-square fluctuation (RMSF) (Fig. 2A). In absence of the p53 peptides, the most mobile regions are located around the first antiparallel α-helices of the C-terminal domain (black asterisks). In the ternary systems, additional peaks are observed for models C (residue 157, red asterisk) and D (residue 10, blue asterisk), in the NTD. These residues belong to a small solvent-exposed loop at the N-terminal segment and MYND domain of Smyd2, afar sites from the peptide-bound crevice. The RMSF plots for the p53 peptides indicate a higher flexibility at the terminal ones (Fig. 2B). The flexibility is especially enhanced at the C-terminal end of the peptide, which forms direct contacts with Smyd2’s CTD. The p53 peptide methylated at Lys370 exhibits higher mobility compared to the unmethylated or methylated at Lys372 one. The localized methylation effect on the residue flexibility was also examined by RMSF estimations at time windows of 30 ns. The obtained range of RMSF, depicted in Fig. S3, suggests
that the methylation at Lys370 (position 0) or Lys372 (position +2) enhances the flexibility at the nearby sites (±1 residues) in comparison with the unmethylated one. This effect is slightly higher for the Lys370 methylation.

3.2. C-terminal domain exhibits different dynamical response to unmethylated and methylated p53 peptides

To characterize the global dynamics of Smyd2 across the different simulations, the dynamic residue cross correlation (DCC) and PCA were performed considering the backbone atoms. The DCC highlights the inter-residue communications, even at long range. Positive and negative correlation ($C_{ij}$) values indicate in-phase and out-of-phase motions of a residue pair ($r_i$ and $r_j$). PCA permits to describe the complex protein motion in a subset of subspaces that largely accounts for most of the motional variance, as defined by the corresponding eigenvectors.

The DCC matrix obtained for models B and C is shown in Fig. 3, and the matrix for models A and D is reported in Fig. S4. Inspection of the matrices reveals noticeable differences in interdomain communications between N- and C-terminal domains. In Model-C, the CTD exhibits strong anticorrelation movements against the NTD segments. This anticorrelation is highly reduced in Model-B, containing the unmethylated peptide (Fig. 3A, compare blue regions in upper and lower triangles). Structural depiction of strong $C_{ij}$ values highlights that the interdomain anticorrelations in Model-C span across different segments of both the domains (Fig. 3B). In Model-B, the anticorrelations are restricted between the first antiparallel $\alpha$-helices of the CTD and MYND segment of the NTD (Fig. S4). Methylation of Lys370, therefore, has as a consequence the establishment of new long-range interactions, particularly between NTD and CTD.

The DCC matrix for Model-A (Fig. S4A, upper triangle) shows strong anticorrelations between the two domains. This result is also consistent with the previously reported observation from sub-$\mu$-second sampling for the model (Chandramouli and Chillemi, 2016). Smyd2 in Model-D exhibits lower interdomain anticorrelations (Fig. S4, lower triangle), similar to Model-B (Fig. 3C, upper triangle). The structural depiction reveals again the presence of the corresponding correlations only between a fewer residues in the first $\alpha$-helix of the CTD and those in the MYND segment of the NTD. Methylation of Lys372 is not capable, therefore, to activate long-range interactions, and in this respect, this system is similar to the unmethylated p53 peptide. At variance, several long-range interactions are present in absence of the p53 peptide.

In order to further characterize the anticorrelated motions highlighted by the DCC analysis, we defined and analyzed two geometric descriptors, the open and slide angles, whose distribution is reported in Fig. 4. These highlight a sort of hinge-like motion of the CTD with respect to the NTD counterpart. In the binary case (Model-A), the distribution of both angles is well
shifted from the X-ray configuration and also above the ternary ones (models B–D). The mean values of the absolute difference in the open angles from the X-ray structure for models A–D were 9.7 (± 2.7), 4.3 (± 2.1), 2.9 (± 1.8), and 4.2 (± 2.0) degree. Similarly, the mean values for the slide angles were 13.7 (± 4.9), 6.1 (± 3.5), 3.8 (± 2.9), and 2.7 (± 1.9) degree.

To compare the Smyd2’s dynamics across the simulations, PCA was performed on a concatenated trajectory that included snapshots from all the models. Projection of trajectory snapshots onto the subspace defined by first three eigenvectors that explains ~70% of motional variance is reported in Fig. S5. It is clear that the dynamical basin of Model-A (binary system) is well separated from the ternary ones (Fig. S5A,B). Further, the larger deviation in mean projection along the corresponding eigenvectors confirms its higher flexibility compared to the ternary ones (Fig. S5C). Among the ternary ones, projections of Model-D overlap yet span a restricted basin compared to the other ternary systems (models B and C).

3.3. p53 methylation at Lys372 has notable effects on the accessibility of Lys370 to the cofactor

We characterized the dynamical features of bound p53 peptides in the ternary complexes by examining the interaction profile, geometric, and structural parameters (Fig. 5). Interaction energy between the p53 methylation sites (Lys370/Lys372) and Smyd2 residues within 15 Å was estimated via electrostatic and vdW terms and represented as boxplots (Fig. 5A). Methylation at Lys370 or Lys372 does not have great influence on the electrostatic interactions (compare gray vs red bars for Lys370 and gray vs blue bars for Lys372). On the contrary, the vdW interactions are increased as indicated by the reduction by ~3.2 and 6 kcal-mol⁻¹ of the median values (white line in Fig. 5A) in models C and D, respectively. The Q1–Q3 quartile range distribution represented in the boxplot, however, shows that the two distributions are significantly different only in the case of methylation.
at Lys372 (model-D vs the unmethylated model-B). Interaction energies between the complete p53 peptide and Smyd2 show a similar trend: no distinct difference in electrostatic interactions except an increase in vdW interactions as we go from models B to D (Fig. S6A). Also, in this case, the boxplot distributions for models D and B are significantly different. Distribution of the gyration radius reveals that p53 methylated at Lys372 maintains a relatively compact structure as compared to the unmethylated or methylated p53 at Lys370. This is also apparent from the time-evolved variations in gyration radius (Fig. S6B). Further, the PCA and corresponding projections along the principal eigenvectors (Fig. 5C) reveal a restricted conformational basin for Lys372-methylated p53, which correlates with other structural characteristics mentioned above.

The accessibility of Lys370, the natural target site for Smyd2-mediated p53 methylation, to the cofactor was assessed by calculating the distance between the amino group of Lys370 and the sulfur atom of AdoMet/AdoHcy that acts as the methyl donor (boxplot representation in Fig. 5D). Lys370 in Model-C is more accessible than when the target peptide is

---

**Fig. 4.** Geometric descriptors characterizing the hinge motion of the CTD for models A–D in black, gray, red, and blue, respectively (refer Fig. 2). (A) Definition of open angle along with its distribution over the last 900 ns. (B) Definition of slide angle and its corresponding distribution. The dashed line indicates the value for the X-ray structure.

**Fig. 5.** p53 interaction profile and conformational dynamics. (A) Boxplot representation of interaction energy (electrostatic and van der Waals terms in kcal-mol\(^{-1}\)) between the methylation site (i.e., Lys370/Lys372 and ±1 adjacent residues) and Smyd2 for models B–D (refer Fig. 1c) in gray, red, and blue, respectively. (B) Distribution of the gyration radius of p53 peptide during the last 900 ns. (C) Projection of p53 structures along the eigen subspace defined by principal vectors 1–2 and 1–3, respectively. (D) Distance between Lys370 amino group nitrogen and the sulfur atom of AdoMet or AdoHcy. (E) Superimposition of representative conformers obtained from clustering.
unmethylated (Model-B). Further, methylation at Lys372 also influences Lys370 accessibility to the sulfur as demonstrated by the increased distance by ∼1.4 Å, even though the difference between the distance distribution in models D and B is not significant. These observations correlate with the increased vDW interactions between the methylated lysines and protein residues (vida supra).

Biochemical characterization of Smyd2 activity via steady-state kinetic and product inhibition experiments has established that Smyd2 operates through a rapid equilibrium random Bi Bi mechanism (Wu et al., 2011). The lysine methylation involves a direct nucleophilic attack of the methyl group leaving the AdoMet by the target amine without the formation of methylprotein intermediate (Wu et al., 2011). Hence, a proper insertion of the target lysine (Lys370 in this case) to access of the methyl group in the deep crevice is indispensable for methylation. Further, Lys372 methylation is shown to partially block the Smyd2-p53 interaction (Huang et al., 2006). Taking together, the current data also highlight the molecular basis for the inhibition of Lys370 methylation by monomethylated Lys372.

To extract representative conformers that can better explain the conformational rearrangements, density-based clustering analysis was performed based on the peptide structural properties (Fig. S7). The representative conformers, extracted from the high dense regions, are reported in Fig. 5E. The conformers are well superimposed between positions −1 to +2 (Leu369–Lys372) except at the terminals with high degree of difference at the C-terminal end that engages in interactions with the Smyd2 CTD. This result agrees with the larger flexibility observed for this region (vida supra). It is also worth to note that the U-shaped conformation of the peptide is well maintained as observed in the X-ray structure.

The comparison of Smyd2 structures in complex with ERα and p53 peptides showed that both peptides adopt similar U-shaped conformation, the respective target lysines being similarly orientated toward the cofactor (Jiang et al., 2014). However, structural difference was observed at residues spanning beyond +3 positions from the target lysine, interacting with distinct residues in the CTD. In line, representative conformers, reported here, show notable difference toward the C-terminal ends. This explains the role of the CTD in substrate stabilization via characteristics interactions.

4. Conclusions

The p53 is the most frequently mutated gene in cancer, reaching a median frequency of 50% mutation rate in all cancers. This results in gain-of-function deregulation of the DNA damage response (Vaughan et al., 2017; Zach et al., 2017), fostering tumor progression (Bartek et al., 2017; Fang et al., 2018), for example, by deregulating its apoptotic targets (Goiran et al., 2018; Sharma et al., 2018), metabolic enzymes (Moon et al., 2019; Sorrentino et al., 2018; Xu et al., 2018), or the AMPK pathway (Houde et al., 2017). Understanding these mechanisms is essential to explore innovative therapeutic venues (Hasna et al., 2018; Malgerud et al., 2017; Siebring-van Olst et al., 2017). At the molecular level, p53 physically binds several targets, such as, for example, MDM2 and MDMX (Arena et al., 2018; Soares et al., 2017) or indeed Smyd2 (Wang et al., 2011). Based on the structural insights on p53 (Joerg and Fersht, 2008, 2016), we have therefore investigated the interaction between p53 and Smyd2.

Thanks to the availability of a supercomputer, we have performed an unusual long MD analysis, up to four µ-second total simulated time. The data shown above sustain the conclusion that the C-terminal domain of Smyd2 (a) has a degree of conformational freedom that is restricted by the physical interaction with the p53 peptide substrate, and (b) shows distinct dynamic properties when interacting with unmethylated and methylated p53 peptides. In turn, (c) the p53 peptide is conformationally confined by Lys372 methylation, which also noticeably affects the Lys370 accessibility to the cofactor. These MD results further expand the knowledge of the p53 biology at the molecular level.

Acknowledgements

We acknowledge Cineca for computing resources. This research was supported by the ‘Departments of Excellence-2018’ Program (Dipartimenti di Eccellenza) of the Italian Ministry of Education, University and Research, DIBAF-Department of University of Tuscia, Project ‘Landscape 4.0 – food, wellbeing and environment’ to GC. This work has been also supported in part by the Medical Research Council (to GM); Associazione Italiana per la Ricerca contro il Cancro (AIRC) to GM IG#20473 (2018-2022); by Regione Lazio through LazioInnova Progetto Gruppo di Ricerca n 85-2017-14986 to GM.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

BC and GC conceived and performed the MD experiments; all authors wrote the paper.
References
Ahmed H, Duan S, Arrowsmith CH, Barsyte-Lovejoy D and Schapira M (2016) An integrative proteomic approach identifies novel cellular SMYD2 substrates. J Proteome Res 15, 2052–2059.
Amadei A, Linssen AB and Berendsen HJ (1993) Essential dynamics of proteins. Proteins 17, 412–425.
Anandakrishnan R, Aguilar B and Onufriev AV (2012) H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res 40, 537–541.
Arnaud DE, Rinaldi C, Le Cam L and Wolf Y (2017) Assessing topological hypervolumes reveals the key role of p53 in medulloblastoma. Cancer Res 77, 4420–4431.
Bartek J Jr, Fornara O, Merchut-Maya JM, Maya-Dorado R, Leticia N, Molina I, Luque E, Linares LK and Le Cam L (2018) p53 and MDM2 cross-regulation mechanisms in medulloblastomas. Mol Oncol 12, 1171–1181.
Bayly CI, Cieplak P, Cornell W and Kollman PA (1993) A well-behaved electrostatic potential based method using force-field charge restraints for deriving atomic charges: the RESP methodology. J Phys Chem 97, 10269–10280.
Bietz S, Urbaczek S, Schulz B and Rarey M (2014) Protoss: a holistic approach to predict tautomers and protonation states in protein-ligand complexes. J Cheminform 6, 12.
Brown MA, Sims RJ, Gottlieb PD and Tucker PW (2006) Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer 5, 26.
Campello RJGB, Moulaei D and Sander J (2013) Density-Based Clustering Based on Hierarchical Density Estimates, pp. 160–172. Springer, Berlin, Heidelberg.
Campello RJGB, Moulaei D, Zimek A and Sander J (2015) Hierarchical density estimates for data clustering, visualization, and outlier detection. ACM Trans Knowl Discov Data 10, 1–51.
Chandramouli B and Chillemi G (2016) Conformational dynamics of lysine methyltransferase Smyd2. Insights into the different substrate crevice characteristics of Smyd2 and Smyd3. J Chem Inf Model 56, 2467–2475.
Chandramouli B, Silverstri V, Scarno M, Ottini L and Chillemi G (2016) Smyd3 open & closed lock mechanism for substrate recruitment: the hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations. Biochim Biophys Acta 1860, 1466–1474.
Charni M, Aloni-Grinstein R, Molchadsky A and Rotter V (2018) p53 on the crossroad between regeneration and cancer. Cell Death Differ 24, 8–14.
Chillemi G, Davidovich P, D’Abramo M, Mametnabiev T, Garabadzhiu AV, Desideri A and Melino G (2013) Molecular dynamics of the full-length p53 monomer. Cell Cycle 12, 3098–3108.
Chillemi G, Kehrloeser S, Bernassola F, Desideri A, Dotsch V, Levine AJ and Melino G (2017) Structural evolution and dynamics of the p53 proteins. Cold Spring Harb Perspect Med 7, 15–29.
Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempest P, Prives C, Gamblin SJ et al. (2004) Regulation of p53 activity through lysine methylation. Nature 432, 353–360.
D’Abramo M, Besker N, Desideri A, Levine AJ, Melino G and Chillemi G (2016) The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain. Oncogene 35, 3272–3281.
Darden T, York D and Pedersen L (1993) Pairwise particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J Chem Phys 98, 10089.
Engeland K (2018) Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM. Cell Death Differ 25, 114–132.
Fang L, Du WW, Lyu J, Dong J, Zhang C, Yang W, He A, Kwok YSS, Ma J, Wu N et al. (2018) Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1. Cell Death Differ 25, 2195–2208.
Ferguson AD, Larsen NA, Howard T, Pollard H, Green I, Grande C, Cheung T, Garcia-Arenas R, Cowen S, Wu J et al. (2011) Structural basis of substrate methylation and inhibition of Smyd2. Structure 19, 1262–1273.
Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, Zhu L, Crew A, Arnold L, Shaaban S et al. (2011) Structural and functional profiling of the human histone methyltransferase Smyd3. PLoS ONE 6, e22290.
Furth N and Aylon Y (2017) The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ 24, 1488–1501.
Furth N, Aylon Y and Oren M (2018) p53 shades of Hippo. Cell Death Differ 25, 81–92.
Gao S, Wang Z, Wang W, Hu X, Chen P, Li J, Feng X, Wong J and Du JX (2017) The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling. *J Biol Chem* **292**, 12702–12712.

Goiran T, Duplan E, Rouland L, El Manaa W, Lauritzen I, Dunys J, You H, Cheeler F and Alves da Costa C (2018) Nuclear p53-mediated repression of autophagy involves PINK1 transcriptional down-regulation. *Cell Death Differ* **25**, 873–884.

Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL, Olson EN et al. (2002) Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. *Nat Genet* **31**, 25–32.

Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R and Nakamura Y (2004) SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. *Nat Cell Biol* **6**, 731–740.

Hasna J, Hague F, Rodat-Despoix L, Geerts D, Leroy C, Tulasne D, Ouadid-Ahidouch H and Kischel P (2018) SMYD2 methylates the kinase domain of type II SMAF. *Cell Death Differ* **25**, 873–884.

Hornak V, Abel R, Okur A, Stockbine B, Roithberg A and Simmerling C (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. *Proteins* **65**, 712–725.

Houde VP, Donzelli S, Sacconi A, Galic S, Hammill JA, Bramson JL, Foster RA, Tsakiridis T, Kemp BE, Grasso G et al. (2017) AMPK β1 reduces tumor progression and improves survival in p53 null mice. *Mol Oncol* **11**, 1143–1155.

Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T and Berger SL (2006) Repression of p53 activity by Smyd2-mediated methylation. *Nature* **444**, 629–632.

Hunter JD (2007) Matplotlib: a 2D graphics environment. *Comput Sci Eng* **9**, 90–95.

Izaguirre JA, Catarello DP, Wozniak JM and Skeel RD (2001) Langevin stabilization of molecular dynamics. *J Chem Phys* **114**, 2090.

Jiang Y, Trescott L, Holcomb J, Zhang X, Brunzelne J, Sirinupong N, Shi X and Yang Z (2014) Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation. *J Mol Biol* **426**, 3413–3425.

Joerger AC and Fersht AR (2008) Structural biology of the tumor suppressor p53. *Annu Rev Biochem* **77**, 557–582.

Joerger AC and Fersht AR (2016) The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. *Annu Rev Biochem* **85**, 375–404.

Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW and Klein ML (1983) Comparison of simple potential functions for simulating liquid water. *J Chem Phys* **79**, 926.

Kaiser AM and Attardi LD (2018) Deconstructing networks of p53-mediated tumor suppression in vivo. *Cell Death Differ* **25**, 93–103.

Kim MP and Lozano G (2018) Mutant p53 partners in crime. *Cell Death Differ* **25**, 161–168.

Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, Shimada Y, Aiko S, Yoshizumi Y, Ichikawa D, Otsuji E et al. (2009) Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. *Carcinogenesis* **30**, 1139–1146.

Li P, Roberts BP, Chakravorty DK and Merz KM (2013) rational design of particle mesh ewald compatible Lennard-Jones parameters for + 2 metal cations in explicit solvent. *J Chem Theory Comput* **9**, 2733–2748.

Li H, Robertson AD and Jensen JH (2005) Very fast empirical prediction and rationalization of protein pKa values. *Proteins* **61**, 704–721.

Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M et al. (2017) Bioinformatic-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. *Mol Oncol* **11**, 1413–1429.

Markham GD, Norrbj P-O and Bock CW (2002) S-adenosylmethionine conformations in solution and in protein complexes: conformational influences of the sulfonium group. *Biochemistry* **41**, 7636–7646.

Marouco D, Garabagiu AV, Melino G and Barlev NA (2013) Lysine-specific modifications of p53: a matter of life and death? *Oncotarget* **4**, 1556–1571.

Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D et al. (2014) SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. *Nature* **510**, 283–287.

McInnes L, Healy J and Astels S (2017) hdbscan: hierarchical density based clustering. *J Open Source Softw* **2**, 205.

Michaud-Agrawal N, Denning EW, Woolf TB and Beckstein O (2011) MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. *J Comput Chem* **32**, 2319–2327.

Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP 4th, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R et al. (2019) p53 represses the mevalonate pathway to mediate tumor suppression. *Cell* **176**, 564–580.e19.

Nemajerova A, Amelio I, Gebel J, Dotsch V, Melino G and Moll UM (2018) Non-oncogenic roles of TAp73:
from multiciliogenesis to metabolism. *Cell Death Differ* **25**, 144–153.

Nguyen H, Allali-Hassani A, Antonysamy S, Chang S, Chen LH, Curtis C, Emtege S, Fan L, Gheyi T, Li F et al. (2015) LLY-507, a cell-active, potent, and selective inhibitor of protein-lysin methyltransferase SMYD2. *J Biol Chem* **290**, 13641–13653.

Olsen JB, Cao XJ, Han B, Chen LH, Horvath A, Richardson TI, Campbell RM, Garcia BA and Nguyen H (2016) Quantitative profiling of the activity of protein lysine methyltransferase SMYD2 Using SILAC-based proteomics. *Mol Cell Proteomics* **15**, 892–905.

Parrales A, Thoenen E and Iwakuma T (2018) The interplay between mutant p53 and the mevalonate pathway. *Cell Death Differ* **25**, 460–470.

Peters MB, Yang Y, Wang B, Füsti-Molnár L, Weaver MN and Merz KM (2010) Structural survey of zinc containing proteins and the development of the zinc AMBER force field (ZAFF). *J Chem Theory Comput* **6**, 2935–2947.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605–1612.

Reynoird N, Mazur PK, Stellfeld T, Flores NM, Löfgren SM, Carlson SM, Brambilla E, Hainaut P, Kaznowska EB, Arrowsmith CH et al. (2016) Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. *Genes Dev* **30**, 772–785.

Roe DR and Cheatham TE (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. *J Chem Theory Comput* **9**, 3084–3095.

Ryckaert J-P, Ciccotti G and Berendsen HJ (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. *J Comput Phys* **23**, 327–341.

Sakamoto LHT, de Andrade RV, Felipe MSS, Motoyama AB and Pittella Silva F (2014) SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. *Leuk Res* **38**, 496–502.

Sharma K, Vu TT, Cook W, Naseri M, Zhan K, Nakajima W and Harada H (2018) p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells. *Mol Oncol* **12**, 788–798.

Siebring-van Olst E, Blijlevens M, de Menezes RX, van der Meulen-Muileman IH, Smit EF and van Beusechem VW (2017) A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment. *Mol Oncol* **11**, 534–551.

Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C et al. (2017) DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. *Mol Oncol* **11**, 612–627.

Sorrentino G, Mantovani F and Del Sal G (2018) The stiff RhoAd from mevalonate to mutant p53. *Cell Death Differ* **25**, 643–645.

Spellmon N, Holcomb J, Trescott L, Sirinupong N and Yang Z (2015) Structure and function of SET and MYND domain-containing proteins. *Int J Mol Sci* **16**, 1406–1428.

Sullivan KD, Galbraith MD, Andrysik Z and Espinosa JM (2018) Mechanisms of transcriptional regulation by p53. *Cell Death Differ* **25**, 133–143.

Swies RF, Wang Z, Algire M, Arrowsmith CH, Brown PJ, Chiang GG, Guo J, Jakob CG, Kennedy S, Li F et al. (2015) Discovery of A-893, a new cell-active benzoaxazinone inhibitor of lysine methyltransferase SMYD2. *ACS Med Chem Lett* **6**, 695–700.

Thomenius MJ, Totman J, Harvey D, Mitchell LH, Riera TV, Cosmopoulos K, Grassian AR, Klaus C, Foley M, Admiraal EA et al. (2018) Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. *PLoS ONE* **13**, e0197372.

Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, McDevitt P, Sinnamon R, Le B, Mas G et al. (2012) Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. *Epinigenetics* **7**, 340–343.

Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE and Berendsen HJC (2005) GROMACS: fast, flexible, and free. *J Comput Chem* **26**, 1701–1718.

Vanequeleff E, Simon S, Marquant G, Garcia E, Klimerak G, Delepine JC, Cieplak P and Dupradaude FY (2011) R.E.D. Server: a web service for deriving RESP and ESP charges and building force field libraries for new molecules and molecular fragments. *Nucleic Acids Res* **39**, W511–W517.

Vaughan CA, Singh S, Grossman SR, Windle B, Deb SP and Deb S (2017) Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells. *Mol Oncol* **11**, 696–711.

Wang J, Cieplak P and Kollman PA (2000) How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? *J Comput Chem* **21**, 1049–1074.

Wang L, Li L, Zhang H, Luo X, Dai J, Zhou S, Gu J, Zhu J, Atadja P, Lu C et al. (2011) Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation. *J Biol Chem* **286**, 38725–38737.
Wu J, Cheung T, Grande C, Ferguson AD, Zhu X, Theriault K and Chen H (2011) Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase. *Biochemistry* **50**, 6488–6497.

Wu D and Prives C (2018) Relevance of the p53-MDM2 axis to aging. *Cell Death Differ* **25**, 169–179.

Xu R, García-Barros M, Wen S, Li F, Lin CL, Hannun YA, Obeid LM and Mao C (2018) Tumor suppressor p53 links ceramide metabolism to DNA damage response through alkaline ceramidase 2. *Cell Death Differ* **25**, 841–856.

Zache N, Lambert JMR, Rökäus N, Shen J, Hainaut P, Bergman J, Wiman KG and Bykov VJN (2017) Mutant p53 targeting by the low molecular weight compound STIMA-1. *Mol Oncol* **11**, 595.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Depiction of the ternary complex and cofactor binding cavity.

**Fig. S2.** Time evolved RMSD variations and distributions.

**Fig. S3.** Minimum and maximum fluctuations of p53 peptide residues.

**Fig. S4.** Dynamic cross correlation matrix for Models A and D.

**Fig. S5.** PCA projections for Smyd2 along principal eigen vectors.

**Fig. S6.** Interaction energy and gyration radius of p53 peptide for models-B–D.

**Fig. S7.** Density based clustering of p53 peptide conformers.